In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

FRANCE 2: French Transcatheter Aortic Valve Intervention Registry: FRANCE 2

Valvular Heart Diseases

Presenter | see Discussant report

Martine Gilard

Access to the congress content with ESC Congress 365


Treatment of high risk patients with severe aortic stenosis and co-morbidities is challenging. Transcatheter aortic valve implantation (TAVI) has revolutionized management. We report the results of the exhaustive prospective multicenter national French Transcatheter Aortic Valve Intervention Registry, FRANCE 2.

The FRANCE 2 registry was established under the authority of the French Societies of Cardiology and Thoracic and Cardio-Vascular Surgery. All TAVIs perormed in France were included, and data were collected prospectively. The primary end-point of the study was mortality from any cause. The standardized outcome definitions of the Valve Academic Research Consortium (VARC) were used. Mortality was adjudicated by an independent clinical events committee.

A total of 3933 patients were enrolled between January 2010 and december 2011 in 34 centres. Mean age was 82.8+7 years; 49.5% were female. All patients were highly symptomatic and at high surgical risk; Edwards SAPIEN and Medtronic CoreValve devices were implanted in 67% and 33% of patients, respectively. Approaches were transarterial (transfemoral: 73%; subclavian: 6 %; transaortic: 1.62 ) or transapical (18%). Procedural success rate was 97%. Mortality at  30 days, 6 month and 1 year was respectively 9.5%, 18% and 24.1%. In a multivariate model, survival was significantly adversely affected by logistic Euroscore, Periprostheticregurgitation grade 2 or higher, trans apical approach, NYHA functional class, creatinemia > 200 μmol/L, dyslipidimia and previous Aortic surgery. We analyzed the evolution in patient and procedural characteristics between the 2 years of the registry (1575 pts in 2010, 2446 pts in 2011).

This is the largest prospective registry and reflects the real-life TAVI experience in high-risk elderly patients in France. TAVI appears to be a reasonable option for a selected population of inoperable or high-risk patients with severe aortic stenosis.

Discussant | see Presenter abstract

Gerhard Schuler

Access to the congress content with ESC Congress 365



711009 - 711010


Clinical Trial & Registry Update III: Updates on Atrial Fibrillation and Valves

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.